The proportion of patients reaching secondary endpoint ( HbA@c < @ mmol/mol without hypoglycemic event or weight gain @ % with baseline glycated hemoglobin > @ mmol/mol was higher for vildagliptin @ % vs @ % in the control arm , odds ratio @ ( @ , @ ) , p < @ .